As co-head of Sullivan & Cromwell's private-equity practice and leader of its California offices, Ressler spent 2010 crafting major mergers and acquisitions in the pharmaceutical and financial sectors.
A special committee to Canadian pharmaceutical company Biovail Corp. relied on her when it completed its $3.2 billion sale to Valeant Pharmaceuticals International Inc. in September. The representation led her to an interesting new client - Valeant. S...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In